NUVALENT INC

NUVALENT’s merger with GSK ends the company, cashing insiders $124/share, and integrates its oncology pipeline into GSK’s global platform, speeding new therapies.

Insider sales spiked as GSK sealed its $124‑per‑share takeover of Nuvalent, revealing a 3.5‑million‑share sell‑off and highlighting how the merger could fast‑track delivery tech into GSK’s pipeline.

Nuvalent CSO sells 2,111 shares on July 9 as a routine tax‑cover move amid Harmony Row’s takeover—insider activity shows no red flag, just standard liquidity work.

Nuvalent CEO’s Rule 10b5‑1 trades reveal disciplined liquidity hedging and confidence in a $124 takeover price, signaling limited upside if Harmony Row wins.

Nuvalent insider buy by Darlene Noci signals strong confidence in its oncology pipeline and potential GSK acquisition, boosting investor optimism.

Nuvalent insider trading shows strategic hedging and long‑term confidence, with the CEO buying deep‑discount shares while selling at market level.

Nuvalent’s CEO buys shares after breakthrough‑therapy news for neladalkib: what insider trades reveal about value, risk, and oncology prospects.

Nuvalent’s CFO insider trades signal confidence in its oncology pipeline, offering investors insights into regulatory, market, and risk dynamics for biotech growth.

Nuvalent’s March 30 insider trades show disciplined liquidity management while leaders remain optimistic about its antibody pipeline and upcoming FDA/EMA approvals.